查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1639226

疫苗佐劑市場機會、成長動力、產業趨勢分析與預測 2025 - 2034

Vaccine Adjuvants Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024年，全球疫苗佐劑市場達到13億美元，預計2025年至2034年複合年成長率為6.5%。透過增強免疫反應，佐劑提高了疫苗的有效性，確保更強、更持久的保護。它們還允許使用較少的抗原，使疫苗更具成本效益，同時提高其整體效率。

市場按產品類型分類，包括皂苷類佐劑、乳液佐劑、病原體成分、顆粒佐劑等。其中，顆粒助劑在2024年引領市場，佔營收的35.4%。全球傳染病流行率不斷上升，加大了對高效疫苗的需求。顆粒佐劑對於改善免疫反應至關重要，使其成為疫苗開發的關鍵要素。它們在增強免疫活性方面的有效性對於解決廣泛的健康問題至關重要，這突顯了它們在疫苗配方中日益成長的重要性。

另一個重要的市場區隔是基於給藥途徑，包括肌肉內、皮下、口服和其他方法。肌肉注射途徑在 2024 年佔據市場主導地位，佔據 59.3% 的佔有率，預計將繼續保持上升趨勢，到 2034 年將達到 14 億美元。對於傳染病高危險群尤其重要。對有效疫苗的需求不斷增加，特別是在全球健康挑戰之後，進一步強調了肌內佐劑給藥的重要性。這種方法增強了疫苗的性能，並在全球疫苗接種活動中發揮關鍵作用。

市場範圍
開始年份 2024年
預測年份 2025-2034
起始值 13億美元
預測值 23億美元
複合年成長率 6.5%

美國疫苗佐劑市場預計將大幅成長，到 2034 年將達到 9.275 億美元。此外，製藥公司、學術機構和研究組織之間的合作正在推動該領域的創新，為新的和改進的佐劑技術鋪平道路，這些技術將在增強未來疫苗配方方面發揮關鍵作用。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 對有效和持久免疫的需求不斷增加
      • 傳染病和流行病日益流行
      • 增加政府和私人資金用於疫苗開發
    • 產業陷阱與挑戰
      • 成本高、開發週期長
      • 嚴格的監管要求
  • 成長潛力分析
  • 監管環境
  • 技術景觀
  • 未來市場趨勢
  • 管道分析
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按產品類型，2021 - 2034 年

  • 主要趨勢
  • 佐劑乳劑
  • 病原體成分
  • 皂苷類佐劑
  • 顆粒佐劑
  • 其他產品類型

第 6 章：市場估計與預測：按管理途徑，2021 - 2034 年

  • 主要趨勢
  • 肌肉注射
  • 皮下
  • 口服
  • 其他給藥途徑

第 7 章：市場估計與預測：按疾病類型，2021 - 2034 年

  • 主要趨勢
  • 傳染病
  • 癌症
  • 其他疾病

第 8 章：市場估計與預測：按應用分類，2021 - 2034 年

  • 主要趨勢
  • 人類疫苗
  • 獸用疫苗

第 9 章：市場估計與預測：按地區分類，2021 - 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：公司簡介

  • Agenus
  • Allergy Therapeutics
  • Aurorium
  • Brenntag Biosector
  • Croda International
  • CSL Limited
  • Dynavax Technologies Corporation
  • EuBiologics
  • GSK plc
  • Merck KGaA
  • Novavax
  • OZ Biosciences
  • Riboxx GmbH
  • Seppic
  • SPI Pharma
簡介目錄
Product Code: 12365

The Global Vaccine Adjuvants Market reached USD 1.3 billion in 2024 and is projected to expand at a CAGR of 6.5% from 2025 to 2034. Vaccine adjuvants are added to vaccines to amplify the immune system's response to the antigen. By enhancing immune responses, adjuvants increase the effectiveness of vaccines, ensuring stronger and longer-lasting protection. They also allow for the use of smaller amounts of the antigen, making vaccines more cost-effective while improving their overall efficiency.

The market is categorized by product types, which include saponin-based adjuvants, adjuvant emulsions, pathogen components, particulate adjuvants, and others. Among these, particulate adjuvants led the market in 2024, accounting for 35.4% of revenue. The rising prevalence of infectious diseases globally has intensified the demand for vaccines with higher efficacy. Particulate adjuvants are crucial in improving immune responses, making them a key element in vaccine development. Their effectiveness in boosting immune activity is vital for tackling widespread health concerns, underlining their growing importance in vaccine formulations.

Another significant market segmentation is based on the route of administration, including intramuscular, subcutaneous, oral, and other methods. The intramuscular route dominated the market in 2024, holding a 59.3% share, and is expected to continue its upward trajectory, reaching USD 1.4 billion by 2034. Vaccines administered intramuscularly with adjuvants have proven to trigger strong and long-lasting immune responses, which are particularly important for populations at higher risk of infectious diseases. The increased demand for effective vaccines, particularly following global health challenges, has further emphasized the importance of intramuscular adjuvant administration. This method enhances vaccine performance and plays a critical role in vaccination campaigns worldwide.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1.3 Billion
Forecast Value$2.3 Billion
CAGR6.5%

U.S. vaccine adjuvants market is anticipated to see substantial growth, reaching USD 927.5 million by 2034. Key U.S. government agencies invest in vaccine research, focusing on improving adjuvants to boost vaccine efficacy against a wide range of diseases. Moreover, collaborative efforts between pharmaceutical companies, academic institutions, and research organizations are driving innovation in the field, paving the way for new and improved adjuvant technologies that will play a pivotal role in enhancing future vaccine formulations.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing demand for effective and long-lasting immunity
      • 3.2.1.2 Growing prevalence of infectious diseases and pandemics
      • 3.2.1.3 Increased government and private funding for vaccine development
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High costs and lengthy development timelines
      • 3.2.2.2 Stringent regulatory requirements
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Pipeline analysis
  • 3.8 Gap analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Adjuvant emulsions
  • 5.3 Pathogen components
  • 5.4 Saponin-based adjuvants
  • 5.5 Particulate adjuvants
  • 5.6 Other product types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Intramuscular
  • 6.3 Subcutaneous
  • 6.4 Oral
  • 6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Infectious diseases
  • 7.3 Cancer
  • 7.4 Other diseases

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Human vaccines
  • 8.3 Veterinary vaccines

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Agenus
  • 10.2 Allergy Therapeutics
  • 10.3 Aurorium
  • 10.4 Brenntag Biosector
  • 10.5 Croda International
  • 10.6 CSL Limited
  • 10.7 Dynavax Technologies Corporation
  • 10.8 EuBiologics
  • 10.9 GSK plc
  • 10.10 Merck KGaA
  • 10.11 Novavax
  • 10.12 OZ Biosciences
  • 10.13 Riboxx GmbH
  • 10.14 Seppic
  • 10.15 SPI Pharma